US-CONGRESS BILLS-119hr10133ih: Fair Prescription Pricing Act of 2026
The Fair Prescription Pricing Act of 2026 has been introduced in the U.S. House of Representatives, aiming to address prescription drug pricing. The bill's specific provisions are not detailed in the excerpt, so the impact on pharmaceutical manufacturers is currently uncertain.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 25, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified; the bill is in early legislative stages.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Introduction of a new bill in Congress that could potentially alter drug pricing regulations, but no specific requirements or changes are yet defined.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B).
What you must do
Monitor the bill's progress and review the full text to assess potential impacts on pricing, rebates, or market access.
Deadline
Not specified; the bill is in early legislative stages.
Source: https://www.govinfo.gov/app/details/BILLS-119hr10133ih
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Guidance: Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities
- FDA to require diversity plan for clinical trials - nature.com
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Second Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- FDA Issues Final Rule Clarifying Evidence of Off-Lab... - Dechert
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act